Table 3.

Univariate and multivariate analysis of the associations between IDDVT and baseline characteristics in training cohort

Variables	Univariate analysis				Multivariate analysis
	β coefficient	OR	95% CI	P-value	β coefficient	OR	95% CI	P-value
Demography parameters
Age (years)	0.047	1.048	1.025–1.072	< 0.001	0.028	1.028	1.003–1.054	0.029
Gender (female)	0.753	2.124	1.342–3.364	0.001	0.638	1.893	1.142–3.137	0.013
Clinical parameters
Lower limb paralysis	−1.744	2.910	1.826–4.639	< 0.001	0.987	2.682	1.623–4.434	< 0.001
Current pneumonia	1.209	3.349	2.002–5.601	< 0.001	0.846	2.331	1.321–4.111	0.003
Atrial fibrillation	1.142	3.132	1.861–5.270	< 0.001	0.989	2.689	1.525–4.743	0.001
Arterial hypertension	−0.132	0.876	0.521–1.476	0.620
Diabetes mellitus	0.138	1.148	0.717–1.838	0.566
Current malignant tumor	1.231	3.425	1.408–8.330	0.007	1.322	3.750	1.442–9.751	0.007
Current uarthritis	−0.790	0.454	0.102–2.021	0.300
Laboratory parameters
Albumin (g/L)	−0.038	0.963	0.912–1.016	0.171
Fast blood glucose (mmol/L)	−0.038	1.030	0.933–1.138	0.555
SCr (μmol/L)	−0.003	0.997	0.990–1.005	0.473
Hcy (μmol/L)	0.014	1.014	0.944–1.090	0.696
INR	−0.184	0.832	0.353–1.960	0.674
Fibrinogen (g/L)	0.015	1.015	0.875–1.177	0.847
D-Dimer (mg/L)	0.032	1.033	0.983–1.085	0.200
CRP (mg/L)	0.004	1.004	0.995–1.012	0.393
hs-CRP (mg/L)	0.008	1.008	0.997–1.019	0.149
Initial treatment in hospital
Anticoagulants	0.374	1.453	0.906–2.331	0.121
Antiplatelet	−0.250	0.779	0.436–1.392	0.399
Lipid-lowering agents	−1.299	1.052	0.288–3.851	0.938
Thrombolysis	−1.258	1.064	0.546–2.071	0.856
Hormonal treatment	−1.300	2.447	0.970–6.172	0.058

NOTE. CI confidence interval; CRP c-reactive protein; Hcy homocysteine; hs-CRP high-sensitivity C-reactive protein; IDDVT isolated distal deep venous thrombosis; OR odds ratio; SCr serum creatinine concentration